Stephanie Stein
Endocrinology, Diabetes & Metabolism · Chevy Chase, MDNPI 1710145255
Payments from drug & device makers
Across 93 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$755
- Novo Nordisk$284
- Abbott$181
- Insulet Corporation$119
- Amneal Pharmaceuticals LLC$96
- Amgen$89
- plus $698 from 16 others
What the payments were for
- Food & beverage$2,21099%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 29 | $755 |
| Novo Nordisk | 12 | $284 |
| Abbott | 8 | $181 |
| Insulet Corporation | 5 | $119 |
| Amneal Pharmaceuticals LLC | 5 | $96 |
| Amgen(2 entities) | 4 | $89 |
| Corcept Therapeutics | 3 | $89 |
| AbbVie | 4 | $84 |
| Sanofi-aventis U.S. LLC | 3 | $75 |
| Antares Pharma, Inc. | 3 | $60 |
| Tandem Diabetes Care, Inc. | 2 | $60 |
| Ascendis Pharma Endocrinology Inc | 2 | $49 |
| Amphastar Pharmaceuticals, Inc. | 2 | $42 |
| Radius Health, Inc. | 2 | $40 |
| Boehringer Ingelheim | 1 | $30 |
| Recordati_rare_diseases_inc. | 1 | $29 |
| Medtronic | 1 | $29 |
| Merck | 2 | $26 |
| Mannkind Corporation | 1 | $25 |
| Alvogen Inc | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Clarus Therapeutics Inc. | 1 | $19 |
How this compares
$2,222 in reported general payments places this provider in the 50th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 112 | $178,572 |
| MounjaroTirzepatide | 128 | $172,560 |
| OzempicSemaglutide | 62 | $124,117 |
| JanuviaSitagliptin Phosphate | 52 | $64,753 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 32 | $64,226 |
| Teriparatide | 19 | $46,491 |
| TradjentaLinagliptin | 12 | $18,598 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $9,722 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $6,503 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $6,421 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $4,775 |
| SynthroidLevothyroxine Sodium | 44 | $4,747 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 31 | $3,800 |
| Levothyroxine Sodium | 104 | $1,798 |
| Metformin Hcl ErMetformin Hcl | 77 | $1,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $30 | $197,170124 claims |
| Lilly USA, LLCMounjaro | $755 | $172,560128 claims |
| Novo NordiskOzempic | $284 | $124,11762 claims |
| MerckJanuvia | $26 | $64,75352 claims |
| Alvogen IncTeriparatide | $22 | $46,49119 claims |
| AbbVieSynthroid | $84 | $4,74744 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $96 | $1,798104 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Chevy Chase
- Jean ParkBaltimore$3.7M
- Michael DempseyRockville$2.7M
- Ilias SpanakisBaltimore$2.6M
- Helena RodbardRockville$2.4M
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Romeu AzevedoCamp Springs$1.1M
- Nicholas ArgentoLaurel$1.1M
- Philip LevinBaltimore$702K
- David BrownRockville$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.